BEOVU 6 mg/.05mL
brolucizumab · INJECTION, SOLUTION · Novartis Pharmaceuticals Corporation
No Recall History
Plain English
BEOVU is a injection, solution containing brolucizumab at 6 mg/.05mL, taken intravitreal. Manufactured by Novartis Pharmaceuticals Corporation.
Key Facts
- Brand Name
- BEOVU
- Generic Name
- brolucizumab
- NDC Code (Product)
0078-0827- Manufacturer
- Novartis Pharmaceuticals Corporation
- Strength
- 6 mg/.05mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVITREAL
- Marketing Status
- Application #
- BLA761125
- Marketing Start
- 10/07/2019
Recall History
No Recall HistoryFrequently Asked Questions
What is BEOVU used for?
BEOVU contains brolucizumab. It is a injection, solution taken intravitreal. Consult your doctor for specific uses.
Is BEOVU a controlled substance?
BEOVU is not classified as a controlled substance by the DEA.
What is the generic name for BEOVU?
The generic name for BEOVU is brolucizumab. There are no other listed brand versions of brolucizumab.
What is the NDC code for BEOVU 6 mg/.05mL?
The NDC (National Drug Code) for BEOVU 6 mg/.05mL is 0078-0827, listed by Novartis Pharmaceuticals Corporation.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)